Functional genomics based on germline genome-wide association studies of endocrine therapy for breast cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Zayas J;Zayas J; Qin S; Qin S; Yu J; Yu J; Ingle JN; Ingle JN; Wang L; Wang L
  • Source:
    Pharmacogenomics [Pharmacogenomics] 2020 Jun; Vol. 21 (9), pp. 615-625. Date of Electronic Publication: 2020 Jun 16.
  • Publication Type:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 100897350 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8042 (Electronic) Linking ISSN: 14622416 NLM ISO Abbreviation: Pharmacogenomics Subsets: MEDLINE
    • Publication Information:
      Publication: London : Future Medicine Ltd
      Original Publication: London : Ashley Publications,
    • Subject Terms:
      Antineoplastic Agents, Hormonal/*therapeutic use ; Breast Neoplasms/*drug therapy ; Breast Neoplasms/*genetics ; Genome-Wide Association Study/*methods ; Genomics/*methods ; Germ Cells/*physiology; Androstadienes/pharmacology ; Androstadienes/therapeutic use ; Antineoplastic Agents, Hormonal/pharmacology ; Aromatase Inhibitors/pharmacology ; Aromatase Inhibitors/therapeutic use ; Breast Neoplasms/epidemiology ; Female ; Germ Cells/drug effects ; Humans ; Selective Estrogen Receptor Modulators/pharmacology ; Selective Estrogen Receptor Modulators/therapeutic use ; Tamoxifen/pharmacology ; Tamoxifen/therapeutic use
    • Abstract:
      Breast cancer is the most common invasive cancer in women worldwide. Functional follow-up of breast cancer genome-wide association studies has led to the discovery of genes that regulate endocrine therapy response in a SNP- and drug-dependent manner. Here, we will present four examples in which functional genomic studies from breast cancer clinical trials led to novel pharmacogenomic insights and molecular mechanisms of selective estrogen receptor modulators and aromatase inhibitors. The approach utilized for studying genetic variability described in this review offers substantial potential for meaningful discoveries that move the field toward precision medicine for patients.
    • References:
      JAMA. 2006 Jun 21;295(23):2727-41. (PMID: 16754727)
      BMC Cancer. 2012 Sep 24;12:422. (PMID: 23006423)
      BMC Genomics. 2014 Feb 01;15:93. (PMID: 24483146)
      J Clin Oncol. 2010 Nov 1;28(31):4674-82. (PMID: 20876420)
      Pharmacogenomics. 2015;16(3):273-85. (PMID: 25712190)
      Int J Mol Sci. 2018 Dec 03;19(12):. (PMID: 30513921)
      Nat Med. 2011 Jun;17(6):715-9. (PMID: 21602804)
      Cancer Res. 2016 Dec 1;76(23):7012-7023. (PMID: 27758888)
      Front Genet. 2015 Jan 13;5:465. (PMID: 25628645)
      PLoS One. 2009 Nov 09;4(11):e7765. (PMID: 19898621)
      Am J Hum Genet. 2003 May;72(5):1117-30. (PMID: 12677558)
      Clin Cancer Res. 2011 Sep 1;17(17):5801-11. (PMID: 21775533)
      Steroids. 2015 Jul;99(Pt A):32-8. (PMID: 25163006)
      Nat Rev Mol Cell Biol. 2019 Aug;20(8):490-507. (PMID: 31147612)
      Hum Mol Genet. 2016 Nov 1;25(21):4819-4834. (PMID: 28173075)
      Cancer Res. 2010 Apr 15;70(8):3278-86. (PMID: 20354183)
      Genome Res. 2010 Nov;20(11):1482-92. (PMID: 20923822)
      Int J Cancer. 2015 Mar 1;136(5):E359-86. (PMID: 25220842)
      Cancer Res. 2008 Sep 1;68(17):7050-8. (PMID: 18757419)
      Mol Pharmacol. 2017 Aug;92(2):175-184. (PMID: 28615284)
      Mol Cancer Ther. 2008 Jun;7(6):1337-46. (PMID: 18524847)
      EMBO Rep. 2018 Mar;19(3):. (PMID: 29335246)
      Breast Cancer Res Treat. 2019 Jun;175(3):567-578. (PMID: 30937657)
      Breast Cancer Res. 2017 Aug 18;19(1):95. (PMID: 28821270)
      Cancer Discov. 2013 Jul;3(7):812-25. (PMID: 23764426)
      PLoS One. 2012;7(5):e36252. (PMID: 22590527)
      Lancet. 2015 Oct 3;386(10001):1341-1352. (PMID: 26211827)
      J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88. (PMID: 9747868)
      Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. (PMID: 20404000)
      J Clin Oncol. 2013 Apr 10;31(11):1398-404. (PMID: 23358971)
      BMC Genomics. 2010 Jun 04;11:357. (PMID: 20525348)
      Mol Endocrinol. 2013 Apr;27(4):657-70. (PMID: 23518928)
      PLoS One. 2012;7(9):e46518. (PMID: 23029544)
      Cancer Cell. 2009 Sep 8;16(3):259-66. (PMID: 19732725)
      Mol Cancer Ther. 2006 Apr;5(4):853-67. (PMID: 16648555)
      PLoS Genet. 2017 Oct 2;13(10):e1007031. (PMID: 28968398)
      Nature. 2016 Apr 20;533(7603):420-4. (PMID: 27096365)
      PLoS One. 2015 Mar 05;10(3):e0119208. (PMID: 25742493)
      Cell Rep. 2017 Jan 31;18(5):1229-1240. (PMID: 28147277)
      Front Genet. 2013 Aug 30;4:166. (PMID: 24009623)
      Clin Pharmacol Ther. 2020 Mar;107(3):662-670. (PMID: 31628858)
      Pharmacogenet Genomics. 2014 Feb;24(2):81-93. (PMID: 24401833)
      Pharmacogenomics. 2014 Mar;15(4):433-47. (PMID: 24624911)
      Clin Pharmacol Ther. 2018 Jul;104(1):201-210. (PMID: 29027195)
      Breast Cancer Res. 2019 Apr 3;21(1):47. (PMID: 30944027)
      J Pharmacol Exp Ther. 2018 Jun;365(3):700-710. (PMID: 29592948)
      Breast Cancer Res. 2012 Mar 09;14(2):R41. (PMID: 22405131)
    • Grant Information:
      R25 GM055252 United States GM NIGMS NIH HHS; T32 GM065841 United States GM NIGMS NIH HHS
    • Contributed Indexing:
      Keywords: GWAS; SNP; breast cancer; endocrine therapy; functional genomics
    • Accession Number:
      0 (Androstadienes)
      0 (Antineoplastic Agents, Hormonal)
      0 (Aromatase Inhibitors)
      0 (Selective Estrogen Receptor Modulators)
      094ZI81Y45 (Tamoxifen)
      NY22HMQ4BX (exemestane)
    • Publication Date:
      Date Created: 20200617 Date Completed: 20210526 Latest Revision: 20211207
    • Publication Date:
      20240829
    • Accession Number:
      PMC7466931
    • Accession Number:
      10.2217/pgs-2019-0191
    • Accession Number:
      32539536